The potential role of local pharmacies to assess asthma control: an Italian cross-sectional study.
Asthma
Asthma control test
Community pharmacies
Control
Treatment compliance
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
05 01 2021
05 01 2021
Historique:
received:
30
04
2020
accepted:
16
12
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
15
5
2021
Statut:
epublish
Résumé
Asthma control and monitoring still represents a challenge worldwide. Although the international guidelines suggest the interplay between secondary and primary care services as an effective strategy to control the disease, community pharmacies' are seldom involved in asthma control assessment. The present cross-sectional study aimed at providing a picture of the relationship between asthma severity and control in community pharmacies within the health district of the city of Verona (Veneto Region, North-Eastern Italy). A call for participation was launched through the Pharmacists' Association of Verona. Patients referring to the participating pharmacies with an anti-asthmatic drug medical prescription and an asthma exemption code were asked to complete the Asthma Control Test (ACT) and a brief questionnaire collecting information on their age, sex, smoking status, aerobic physical exercise and usual asthma therapy, which also defined asthma severity. A multinomial logistic regression model was fitted to investigate the risk of uncontrolled as well as poorly controlled vs. controlled asthma (base). Results were expressed as relative risk ratios (RRR) with 95% confidence interval (95%CI). Fifty-seven community pharmacies accepted to participate and 584 asthmatic patients (54% females; mean-age: 51 ± 19 years) were consecutively recruited from 1st January to 30th June 2018 (6 months). Based upon ACT score 50.5% patients had a controlled asthma, 22.3% a poorly controlled and 27.2% uncontrolled. A variable proportion of patients with uncontrolled asthma were observed for every level of severity, although more frequently with mild persistent form of asthma. Most patients (92%) self-reported regular compliance with therapy. At multinomial regression analysis, patients under regular asthma treatment course (RRR = 0.33; 95%CI: 0.15; 0.77) were less likely to have an ACT< 16 compared to those not taking medications regularly. Overall, our findings highlighted an unsatisfactory asthma control in the general population, independently of the severity level of the disease. Community pharmacies could be a useful frontline interface between patients and the health care services, supporting an effective asthma management plan, from disease assessment and monitoring treatment compliance to referral of patients to specialist medical consultancies.
Sections du résumé
BACKGROUND
Asthma control and monitoring still represents a challenge worldwide. Although the international guidelines suggest the interplay between secondary and primary care services as an effective strategy to control the disease, community pharmacies' are seldom involved in asthma control assessment. The present cross-sectional study aimed at providing a picture of the relationship between asthma severity and control in community pharmacies within the health district of the city of Verona (Veneto Region, North-Eastern Italy).
METHODS
A call for participation was launched through the Pharmacists' Association of Verona. Patients referring to the participating pharmacies with an anti-asthmatic drug medical prescription and an asthma exemption code were asked to complete the Asthma Control Test (ACT) and a brief questionnaire collecting information on their age, sex, smoking status, aerobic physical exercise and usual asthma therapy, which also defined asthma severity. A multinomial logistic regression model was fitted to investigate the risk of uncontrolled as well as poorly controlled vs. controlled asthma (base). Results were expressed as relative risk ratios (RRR) with 95% confidence interval (95%CI).
RESULTS
Fifty-seven community pharmacies accepted to participate and 584 asthmatic patients (54% females; mean-age: 51 ± 19 years) were consecutively recruited from 1st January to 30th June 2018 (6 months). Based upon ACT score 50.5% patients had a controlled asthma, 22.3% a poorly controlled and 27.2% uncontrolled. A variable proportion of patients with uncontrolled asthma were observed for every level of severity, although more frequently with mild persistent form of asthma. Most patients (92%) self-reported regular compliance with therapy. At multinomial regression analysis, patients under regular asthma treatment course (RRR = 0.33; 95%CI: 0.15; 0.77) were less likely to have an ACT< 16 compared to those not taking medications regularly.
CONCLUSIONS
Overall, our findings highlighted an unsatisfactory asthma control in the general population, independently of the severity level of the disease. Community pharmacies could be a useful frontline interface between patients and the health care services, supporting an effective asthma management plan, from disease assessment and monitoring treatment compliance to referral of patients to specialist medical consultancies.
Identifiants
pubmed: 33402150
doi: 10.1186/s12889-020-10080-1
pii: 10.1186/s12889-020-10080-1
pmc: PMC7784353
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19Références
J Allergy Clin Immunol. 2007 Dec;120(6):1360-7
pubmed: 17981317
J Allergy Clin Immunol. 2004 Jan;113(1):59-65
pubmed: 14713908
J Allergy Clin Immunol. 2002 Jul;110(1):58-64
pubmed: 12110821
J Clin Med. 2019 Jul 28;8(8):
pubmed: 31357728
Curr Opin Pulm Med. 2017 Jan;23(1):62-70
pubmed: 27755160
Ann Allergy Asthma Immunol. 2007 Feb;98(2):146-52
pubmed: 17304881
Med J Aust. 2004 Feb 2;180(3):113-7
pubmed: 14748672
Allergy. 2003 Mar;58(3):221-8
pubmed: 12653796
Eur Respir J. 2008 Sep;32(3):812; author reply 812
pubmed: 18757706
World Allergy Organ J. 2016 Dec 14;9(1):42
pubmed: 28031774
Eur Ann Allergy Clin Immunol. 2014 Mar;46(2):74-82
pubmed: 24739126
World Allergy Organ J. 2017 Apr 6;10(1):13
pubmed: 28413571
J Allergy Clin Immunol. 2004 Jul;114(1):40-7
pubmed: 15241342
Adv Ther. 2017 Jun;34(6):1466-1481
pubmed: 28536998
J Allergy Clin Immunol. 2006 Mar;117(3):549-56
pubmed: 16522452
Bull World Health Organ. 2005 Jul;83(7):548-54
pubmed: 16175830
Allergy. 2005 Dec;60(12):1505-10
pubmed: 16266382
Thorax. 2007 Jun;62(6):496-502
pubmed: 17251316
J Asthma. 2014 Feb;51(1):91-6
pubmed: 24040887
J Allergy Clin Immunol. 2016 Oct;138(4):1030-1041
pubmed: 27720017
Eur Ann Allergy Clin Immunol. 2017 Sep;49(5):225-230
pubmed: 28884990
Am J Respir Crit Care Med. 2004 Oct 15;170(8):836-44
pubmed: 15256389
Respir Med. 2013 Nov;107(11):1659-66
pubmed: 24045118
Ann Allergy Asthma Immunol. 2017 Feb;118(2):161-165
pubmed: 27887807
Mayo Clin Proc. 2008 Jul;83(7):814-20
pubmed: 18613998
Respir Med. 2006 Aug;100(8):1407-14
pubmed: 16386885
Int J Clin Pharm. 2015 Oct;37(5):726-33
pubmed: 26148860
ERJ Open Res. 2020 Apr 27;6(2):
pubmed: 32363204